Efficacy_and_cost_effectiveness_of_adjuvant_chemotherapy_in_women_with_node-negative_breast_cancer._A_decision-analysis_model._BACKGROUND._In_1988_the_National_Cancer_Institute_issued_a_Clinical_Alert_that_has_been_widely_interpreted_as_recommending_that_all_women_with_node-negative_breast_cancer_receive_adjuvant_chemotherapy._Acceptance_of_this_recommendation_is_controversial,_since_many_women_who_would_not_have_a_recurrence_would_be_treated._METHODS._Using_a_decision-analysis_model,_we_studied_the_cost_effectiveness_of_chemotherapy_in_cohorts_of_45-year-old_and_60-year-old_women_with_node-negative_breast_cancer_by_calculating_life_expectancy_as_adjusted_for_quality_of_life._The_analysis_evaluated_different_scenarios_of_the_benefit_of_therapy:_improved_disease-free_survival_for_five_years,_with_a_lesser_effect_on_overall_survival_(base_line);_a_lifelong_benefit_from_chemotherapy;_and_a_benefit_in_disease-free_survival_with_no_change_in_overall_survival_by_year_10._The_base-line_analysis_assumed_a_30_percent_reduction_in_the_relative_risk_of_recurrence_for_five_years_after_treatment._RESULTS._For_the_45-year-old_woman,_the_base-line_analysis_found_an_average_lifetime_benefit_from_chemotherapy_of_5.1_quality-months_at_a_cost_of_$15,400_per_quality-year._The_60-year-old_women_gained_4.0_quality-months_at_a_cost_of_$18,800_per_quality-year._Under_the_more_and_less_optimistic_scenarios,_the_benefit_of_chemotherapy_varied_from_1.4_to_14.0_quality-months_for_both_groups._CONCLUSIONS._Chemotherapy_substantially_increases_the_quality-adjusted_life_expectancy_of_an_average_woman_at_a_cost_comparable_to_that_of_other_widely_accepted_therapies._This_benefit_decreases_markedly_if_the_changes_in_long-term_survival_are_less_than_in_disease-free_survival._Given_its_uncertain_duration,_the_benefit_may_be_too_small_for_many_women_to_choose_chemotherapy._Selective_use_of_chemotherapy_to_maximize_the_benefit_to_individual_patients_may_be_possible_with_refinements_in_risk_stratification_and_explicit_assessment_of_the_patients'_risk_preferences.